Bioequivalence of Fixed-Dose Combinations of Dapagliflozin/Metformin Relative to Single Components in Healthy Subjects

Bioequivalence of Fixed-Dose Combinations of Dapagliflozin/Metformin Relative to Single Components in Healthy Subjects

The aim of this study was to assess the bioequivalence and tolerability of 2 strengths of dapagliflozin (DAPA)/metformin extended-release (MET-XR) FDCs versus their individual components (ICs) in healthy subjects.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical therapeutics 2015-08, Vol.37 (8), p.e98-e99
Hauptverfasser: Boulton, D.W, Chang, M, Griffen, S.C, Kitaura, C, Lubin, S, Pollack, A, LaCreta, F
Format: Artikel
Sprache:eng
Schlagworte:
Internal Medicine
Medical Education
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aim of this study was to assess the bioequivalence and tolerability of 2 strengths of dapagliflozin (DAPA)/metformin extended-release (MET-XR) FDCs versus their individual components (ICs) in healthy subjects.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2015.05.283